Press release Biocartis Group NV

Results of the Annual Shareholders’ Meeting held on 12 May 2023

PRESS RELEASE: REGULATED INFORMATION
12 May 2023, 17:40 CEST

Results of the Annual Shareholders’ Meeting held on 12 May 2023

Mechelen, Belgium, 12 May 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), held its annual shareholders' meeting today at its offices in Mechelen, Belgium.

The shareholders approved all items on the agenda, with the exception of the agenda item regarding the approval of certain features of the Share Option Plan 2023. Following the shareholders’ meeting of today, the Company’s board of directors consists of Christian Reinaudo, Ann-Christine Sundell, Christine Kuslich and Luc Gijsens BV, represented by Luc Gijsens (whose current mandate will end at the annual shareholders’ meeting to be held in 2024), as well as SBV BV, represented by Herman Verrelst, and Bryan Dechairo (whose current mandate will end at the annual shareholders’ meeting to be held in 2025).

All documents relating to the annual shareholders’ meeting can be consulted on the website of the Company.

--- END ---

More information:

Renate Degrave
Head of Corporate Communications & Investor Relations Biocartis
e-mail     [e-mail]
tel         [phone]
mobile   [phone]

About Biocartis

With its revolutionary and proprietary Idylla platform, Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla's continuously expanding menu of molecular diagnostic tests address key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung and liver cancer, as well as for COVID-19, Flu, RSV and sepsis. For more information, visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_ , Facebook or LinkedIn.